Contact us

877-469-1TRM
424-208-8866

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

A Randomized, Multicenter, Double-Blind Phase 3 Study Of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
HR+/HER2-Negative Metastatic Breast Cancer PD-0332991 (Palbocicilib) III Closed to Accrual